11.04.19 10:54

Klinik für Dermatologie (Prof. Dr. Bernhard Homey) ist Projektpartner

Personalisierte Medizin für chronisch entzündliche Hauterkrankungen

Von: Redaktion

Ein groß angelegtes IMI Projekt wird die Gründe und Mechanismen von Atopischer Dermatitis (Neurodermitis) und Psoriasis (Schuppenflechte) untersuchen.

Am ersten April 2019 startete das EU-Projekt BIOMAP (Biomarkers in Atopic Dermatitis und Psoriasis) mit dem Ziel, die Lebensqualität von Patientinnen und Patienten zu verbessern, die an diesen Erkrankungen leiden. Das auf fünf Jahre angelegte Projekt wird die Daten von mehr als 50.000 Patientinnen und Patienten analysieren und vor allem bislang ungelöste Schlüsselfragen bei der Behandlung von Atopischer Dermatitis und Psoriasis untersuchen. Die Wissenschaftlerinnen und Wissenschaftler sind davon überzeugt, dass das Projekt einen breiten Einfluss für das Verständnis der Erkrankungen an sich, heutiger und zukünftiger Therapien haben wird. Der BIOMAP-Projektverbund umfasst 26 akademische und fünf industrielle Partner sowie fünf Patientenvereinigungen. Die Europäische Initiative Innovative Medizin (IMI) and die teilnehmenden Pharmafirmen fördern dieses erste Projekt auf dem Gebiet der Dermatologie mit 20,8 Mio Euro.

Englische Original-Pressemitteilung

On 1 April, 2019, the EU-funded research project BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than 50 000 patients, the five-year project will have a broad impact on disease understanding, patient care and future therapies. The team comprises 26 academic and five industry partners as well as five patient organisations. The European Innovative Medicines Initiative (IMI) and the participating pharma companies provide EUR 20.8 million funding for the first IMI project in the field of dermatology.

Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment. Resulting in significant morbidity and an increased risk for associated conditions such as arthritis and asthma, inflammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems. Yet, despite many years of research, there are still significant gaps in the understanding of both conditions.

The renowned clinicians and scientists of BIOMAP, who have now joined forces in a large public-private partnership, will examine the causes and mechanisms of these conditions. By analysing the largest collection of patient data ever and performing advanced molecular investigations at the single cell level and in the tissue context, they aim at identifying biomarkers for variations in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics. BIOMAP is the first IMI project in the field of dermatology.

Assuming that the variation in symptoms and disease progression reflects fundamental differences at a molecular level, the researchers will take a holistic, systematic approach to identify patient subgroups with different subtypes of disease and different responses to therapy. Additionally, the BIOMAP consortium aims to examine the genetic and environmental factors which exert additional influence on disease outcome and treatment response as well as measurable factors in the patients' blood and skin which reveal the disease subtype they belong to. In an unprecedented analysis of harmonised clinical and molecular data from more than 50 000 patients as well as healthy individuals, the BIOMAP researchers aim to derive a new model for disease classification in order to provide each patient with optimal treatment and an individualised therapy scheme.

Professor Stephan Weidinger, academic coordinator of the consortium and internationally-renowned clinician scientist from the University of Kiel Germany, hopes that "atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular 'signature'."

Dr Paul Bryce, the consortium's project lead from Sanofi, states that "by understanding these diseases as comprehensively as possible, any molecularly defined endotypes we will find will help to drive the next generation of precision therapies that can improve the lives of patients."

"The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene", expects BIOMAP's academic co-coordinator Professor Catherine Smith from King's College London.

"BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases", says Dr Witte Koopmann, industrial co-project lead from LEO Pharma.

The voices of patients living with Atopic Dermatitis and Psoriasis will be at the heart of BIOMAP, through the establishment of a Patient Advisory Group. It will ensure that patients' insights, opinions and wishes are taken into account across all the multiple components of the project.

Helen McAteer, Chief Executive of the Psoriasis Association and member of the BIOMAP Patient Advisory Group, described the ambition and purpose of BIOMAP as "a major opportunity to improve the lives of people with skin disease - we need information on why and who is going to develop severe disease, and also new approaches to treatment. Involving a Patient Advisory Group puts the needs of the patients at the heart of the project from the very beginning. By providing a European-wide platform for collaboration, BIOMAP will enable sharing of know-how and data about atopic dermatitis and psoriasis so that we can all work together like never before".

BIOMAP is funded by the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 821511 and in-kind contributions of the participating pharma companies. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

The project will officially kick off its activities with a first meeting in London on 10-12 April, 2019.

Coordination:

Christian-Albrechts-Universität zu Kiel, Prof. Stephan Weidinger
Project Lead: Sanofi-Aventis Deutschland GmbH, Dr Paul Bryce
Project Management: EURICE - European Research and Project Office GmbH, Dr Verena Peuser, Dr Bianca Dibari
undefinedWebsite

Biomap Partners

Germany

Christian-Albrechts-Universität zu Kiel

Klinikum rechts der Isar der Technischen Universität München
Universitätsklinikum Hamburg-Eppendorf

Heinrich-Heine-Universität Düsseldorf

Hahn-Schickard-Gesellschaft für angewandte Forschung e.V.

Eurice - European Research and Project Office GmbH

Sanofi-Aventis Deutschland GmbH

Boehringer Ingelheim International GmbH

Technische Universität München

United Kingdom

King's College London

University of Bristol

University of Dundee

London School of Hygiene & Tropical Medicine

Pfizer Limited

Sweden

Karolinska Institutet

Netherlands

Academisch Ziekenhuis Leiden

Radboud University Medical Center

Academisch Medisch Centrum Universiteit van Amsterdam

Luxemburg

Université du Luxembourg

Information Technology for Translational Medicine

Finland

Tampereen Yliopisto/ Tampere University

Tartu Ülikool/ University of Tartu

Itä-Suomen Yliopisto/ University of Eastern Finland

Austria

Austrian Institute of Technology GmbH

Universität Wien

Denmark

Københavns Universitet

Den Selvejende Institution Dansk Børneastma Center

LEO Pharma A/S

Switzerland

Centre Hospitalier Universitaire Vaudois

Ireland

Trinity College Dublin

Belgium

UCB Biopharma SPRL

About IMI

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu

Press Contacts

Coordination:

Christian-Albrechts-Universität zu Kiel

Prof. Stephan Weidinger

Phone +49 431 500 21110

Email sweidinger@dermatology.uni-kiel.de

Project Lead:

Sanofi-Aventis Deutschland GmbH

Dr Paul Bryce

Phone +1 617 452 9604

Email Paul.Bryce@sanofi.com

Project Management:

EURICE - European Research and Project Office GmbH

Dr Verena Peuser

Phone +49 30 374415832

Email v.peuser@eurice.eu

 

Verantwortlich für den Inhalt: E-Mail sendenStabsstelle Presse und Kommunikation